BCL-XL is an actionable target for treatment of malignant pleural mesothelioma (original) (raw)
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy
Elena Varin
Carcinogenesis, 2010
View PDFchevron_right
Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma
Nilanjan Chaudhuri
Acta Oncologica, 2006
View PDFchevron_right
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
Surein Arulananda
Cell Death Discovery, 2021
View PDFchevron_right
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma
Michael Jaklitsch
2002
View PDFchevron_right
Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis
Ralph Schmid
Cell Death & Disease, 2021
View PDFchevron_right
Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
Yasser Bustanji
Biomolecules & therapeutics, 2024
View PDFchevron_right
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
C. Herold-mende
Oncogene, 2008
View PDFchevron_right
What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
Ashley Ng
Cell Death & Differentiation, 2022
View PDFchevron_right
An inhibitor of Bcl2 family proteins induces regression of solid tumours
Letai Le
Nature, 2005
View PDFchevron_right
BCL-2 protein family: attractive targets for cancer therapy
deeksha kaloni
Apoptosis
View PDFchevron_right
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
Yulian Ramirez, Mike-Andrew Westhoff
Oncotarget, 2015
View PDFchevron_right
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Karen Williams
Molecular Cancer Therapeutics, 2013
View PDFchevron_right
MCL-1 is a key determinant of breast cancer cell survival: Validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor
George Sheppard
Molecular cancer therapeutics, 2015
View PDFchevron_right
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Nadege Gitego
Nature Communications, 2022
View PDFchevron_right
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers
Eugene Lifshits
Cancer research, 2014
View PDFchevron_right
Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer
Brona Murphy
Experimental oncology, 2012
View PDFchevron_right
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer
Faria Siddiqui
Cancer Discovery
View PDFchevron_right
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Mohamed Rahmani
Cancers, 2021
View PDFchevron_right
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Violeta Jazmin Forneron Sanchez
Molecular cancer research : MCR, 2016
View PDFchevron_right
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl2 and Bax in inflammatory and malignant pleural lesions
Antonio Marchetti
Lung Cancer, 2005
View PDFchevron_right
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis
maricela ramirez
Cell death & disease, 2018
View PDFchevron_right
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Surein Arulananda
Cell Death & Disease, 2019
View PDFchevron_right
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
youngchul song
Cancer Cell, 2013
View PDFchevron_right
Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer
Anton-Scott Goustin
Recent patents on anti-cancer drug discovery, 2008
View PDFchevron_right
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Nghi La, Lisa Belmont, Wayne Fairbrother
Science translational medicine, 2015
View PDFchevron_right
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
Ralph Schmid
Frontiers in Oncology, 2020
View PDFchevron_right
Knockdown of COPA, Identified by Loss-of-Function Screen, Induces Apoptosis and Suppresses Tumor Growth in Mesothelioma Mouse Model
Masakazu Kohda
Genomics, 2010
View PDFchevron_right
RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Insights into Novel Drugs Targeting Bcl-2 Protein as Potential Anti- cancer Agents
safaa kishk
2020
View PDFchevron_right
Cisplatin Resistance in Malignant Pleural Mesothelioma
Parviz Behnam-motlagh
Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, 2012
View PDFchevron_right
Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2
Zaneta Nikolovska-Coleska
Cancer Research, 2004
View PDFchevron_right
Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells
Hung Pham
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
View PDFchevron_right
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Martin Dyer
Cell Death & …, 2008
View PDFchevron_right
Anti-apoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity
Rens Braster
Blood, 2014
View PDFchevron_right
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Erick Morris
Oncotarget, 2018
View PDFchevron_right